Cipla seeks DCGI nod for import of Moderna’s COVID-19 vaccine: Sources
Cipla seeks DCGI nod for import of Moderna’s COVID-19 vaccine: Sources
Moderna's method to protect against Covid-19 relies on messenger RNA (mRNA) to program cells to generate immunity to the coronavirus. The vaccine has shown more than 90 per cent efficacy in clinical trials in protecting against COVID-19.